amiodarone has been researched along with Out-of-Hospital Cardiac Arrest in 46 studies
Amiodarone: An antianginal and class III antiarrhythmic drug. It increases the duration of ventricular and atrial muscle action by inhibiting POTASSIUM CHANNELS and VOLTAGE-GATED SODIUM CHANNELS. There is a resulting decrease in heart rate and in vascular resistance.
amiodarone : A member of the class of 1-benzofurans that is 1-benzofuran substituted by a butyl group at position 2 and a 4-[2-(diethylamino)ethoxy]-3,5-diiodobenzoyl group at position 3. It is a cardiovascular drug used for the treatment of cardiac dysrhythmias.
Out-of-Hospital Cardiac Arrest: Occurrence of heart arrest in an individual when there is no immediate access to medical personnel or equipment.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Amiodarone and lidocaine have not been shown to have a clear survival benefit compared to placebo for out-of-hospital cardiac arrest (OHCA)." | 9.69 | Survival by time-to-administration of amiodarone, lidocaine, or placebo in shock-refractory out-of-hospital cardiac arrest. ( Daya, MR; Jui, J; Lupton, JR; Neth, MR; Newgard, CD; Sahni, R; Wittwer, L, 2023) |
| "In this randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care, in adults who had nontraumatic out-of-hospital cardiac arrest, shock-refractory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular access." | 9.22 | Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. ( Aufderheide, TP; Brienza, AM; Brown, SP; Callaway, CW; Christenson, J; Colella, MR; Daya, M; Desvigne-Nickens, P; Dorian, P; Dunford, JV; Egan, D; Gray, PC; Gray, R; Idris, AH; Kudenchuk, PJ; Leroux, B; Morrison, LJ; Nichol, G; Ornato, JP; Rea, T; Seals, N; Stiell, IG; Straight, R; Vaillancourt, C; Vilke, GM; Weisfeldt, ML; Wittwer, L, 2016) |
| "Clinical trials for patients with shock-refractory out-of-hospital cardiac arrest (OHCA), including the Amiodarone, Lidocaine or Placebo (ALPS) trial, have been unable to demonstrate definitive benefit after treatment with antiarrhythmic drugs." | 8.12 | Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest. ( Christenson, J; Davis, D; Daya, MR; Dorian, P; Grunau, B; Kudenchuk, P; Lane, DJ; Lupton, J; Okubo, M; Rea, T; Scheuermeyer, F; Vaillancourt, C; Wang, HE; Yannopoulos, D, 2022) |
| " We included adult patients with shockable rhythms, such as ventricular fibrillation and pulseless ventricular tachycardia, who were administered either lidocaine or amiodarone." | 8.12 | Comparison of the effects of lidocaine and amiodarone for out-of-hospital cardiac arrest patients with shockable rhythms: a retrospective observational study from a multicenter registry. ( Amagasa, S; Fukushima, F; Kashiura, M; Kishihara, Y; Moriya, T; Yasuda, H, 2022) |
| "International guidelines recommend amiodarone for out-of-hospital cardiac arrest (OHCA) in refractory ventricular fibrillation (VF)." | 8.02 | Time to amiodarone administration and survival outcomes in refractory ventricular fibrillation. ( Bosley, E; Doan, TN; Rashford, S; Schultz, BV; Wilson, D; Wissa, J, 2021) |
| "The 2015 AHA guidelines recommend that amiodarone should be used for patients with refractory ventricular fibrillation (RVF)." | 7.91 | Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data. ( Choi, HJ; Kim, G; Kim, YJ; Lee, CA; Lee, DK; Moon, HJ; Oh, J; Oh, YT; Park, SM; Yang, HC, 2019) |
| "This nationwide study suggested no significant in-hospital mortality association between nifekalant and amiodarone for cardiogenic out-of-hospital cardiac arrest patients with ventricular fibrillation/persistent ventricular tachycardia on hospital arrival." | 7.83 | Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. ( Fukuda, R; Fushimi, K; Ishinokami, S; Kitahashi, A; Matsui, H; Oyanagi, M; Tagami, T; Unemoto, K; Yasunaga, H, 2016) |
| "The latest resuscitation guidelines recommend the use of amiodarone in adult patients with out-of-hospital cardiac arrest (OHCA) and refractory ventricular fibrillation (VF) to improve the rates of return of spontaneous circulation." | 7.83 | Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study. ( Fushimi, K; Ishinokami, S; Kaneko, J; Kuno, M; Matsui, H; Tagami, T; Tanaka, C; Unemoto, K; Yasunaga, H, 2016) |
| " Of these, 25 patients were treated with nifekalant or amiodarone in response to ventricular fibrillation that was resistant to two or more shocks." | 7.80 | Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. ( Aibara, K; Goto, K; Harayama, N; Isa, Y; Kamochi, M; Nagata, K; Nihei, S; Sata, T, 2014) |
| "Background The effects of amiodarone and lidocaine on the return of spontaneous circulation (ROSC) in relation to time to treatment in patients with out-of-hospital cardiac arrest is not known." | 5.51 | Effect of Time to Treatment With Antiarrhythmic Drugs on Return of Spontaneous Circulation in Shock-Refractory Out-of-Hospital Cardiac Arrest. ( Cheskes, S; Dorian, P; Lebovic, G; Lin, S; Rahimi, M, 2022) |
| "In this prespecified analysis of a randomized, placebo-controlled clinical trial, we compared the differences in survival to hospital discharge in adults with shock-refractory ventricular fibrillation/pulseless ventricular tachycardia out-of-hospital cardiac arrest who were randomly assigned by emergency medical services personnel to an antiarrhythmic drug versus placebo in the ALPS trial (Resuscitation Outcomes Consortium Amiodarone, Lidocaine or Placebo Study), when stratified by the intravenous versus intraosseous route of administration." | 5.34 | Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest. ( Barbic, D; Christenson, J; Daya, MR; Dorian, P; Herdeman, C; Idris, A; Kudenchuk, PJ; Leroux, BG; Lupton, JR; Menegazzi, JJ; Mody, P; Morrison, LJ; Newgard, CD; Ornato, JP; Rea, TD; Sopko, G; Vilke, GM, 2020) |
| "In this randomized, double-blind trial, we compared parenteral amiodarone, lidocaine, and saline placebo, along with standard care, in adults who had nontraumatic out-of-hospital cardiac arrest, shock-refractory ventricular fibrillation or pulseless ventricular tachycardia after at least one shock, and vascular access." | 5.22 | Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest. ( Aufderheide, TP; Brienza, AM; Brown, SP; Callaway, CW; Christenson, J; Colella, MR; Daya, M; Desvigne-Nickens, P; Dorian, P; Dunford, JV; Egan, D; Gray, PC; Gray, R; Idris, AH; Kudenchuk, PJ; Leroux, B; Morrison, LJ; Nichol, G; Ornato, JP; Rea, T; Seals, N; Stiell, IG; Straight, R; Vaillancourt, C; Vilke, GM; Weisfeldt, ML; Wittwer, L, 2016) |
| "Guidelines for treatment of out-of-hospital cardiac arrest (OOH-CA) with shockable rhythm recommend amiodarone, while lidocaine may be used if amiodarone is not available." | 4.93 | Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis. ( Arcadipane, A; Corredor, C; Panarello, G; Pellis, T; Ristagno, G; Sanfilippo, F; Santonocito, C, 2016) |
| "American Heart Association Advanced Cardiac Life Support (ACLS) guidelines support the use of either amiodarone or lidocaine for cardiac arrest caused by ventricular tachycardia or ventricular fibrillation (VT/VF) based on studies of out-of-hospital cardiac arrest." | 4.31 | Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest. ( Bradley, SM; Cranford, JA; Kronick, SL; Nawer, H; Neumar, RW; Wagner, D, 2023) |
| "Clinical trials for patients with shock-refractory out-of-hospital cardiac arrest (OHCA), including the Amiodarone, Lidocaine or Placebo (ALPS) trial, have been unable to demonstrate definitive benefit after treatment with antiarrhythmic drugs." | 4.12 | Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest. ( Christenson, J; Davis, D; Daya, MR; Dorian, P; Grunau, B; Kudenchuk, P; Lane, DJ; Lupton, J; Okubo, M; Rea, T; Scheuermeyer, F; Vaillancourt, C; Wang, HE; Yannopoulos, D, 2022) |
| " We included adult patients with shockable rhythms, such as ventricular fibrillation and pulseless ventricular tachycardia, who were administered either lidocaine or amiodarone." | 4.12 | Comparison of the effects of lidocaine and amiodarone for out-of-hospital cardiac arrest patients with shockable rhythms: a retrospective observational study from a multicenter registry. ( Amagasa, S; Fukushima, F; Kashiura, M; Kishihara, Y; Moriya, T; Yasuda, H, 2022) |
| "International guidelines recommend amiodarone for out-of-hospital cardiac arrest (OHCA) in refractory ventricular fibrillation (VF)." | 4.02 | Time to amiodarone administration and survival outcomes in refractory ventricular fibrillation. ( Bosley, E; Doan, TN; Rashford, S; Schultz, BV; Wilson, D; Wissa, J, 2021) |
| "We retrospectively evaluated survival in 160 consecutive adults with refractory ventricular fibrillation/ventricular tachycardia out-of-hospital cardiac arrest treated with the University of Minnesota (UMN) ECPR protocol (transport with ongoing cardiopulmonary resuscitation [CPR] to the cardiac catheterization laboratory for ECPR) compared with 654 adults who had received standard CPR in the amiodarone arm of the ALPS trial (Amiodarone, Lidocaine, or Placebo Study)." | 3.96 | Improved Survival With Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated With Prolonged Resuscitation. ( Aufderheide, TP; Bartos, JA; Carlson, C; Conterato, M; Duval, S; Frascone, RJ; Grunau, B; John, R; Kalra, R; Raveendran, G; Ripeckyj, A; Trembley, A; Yannopoulos, D, 2020) |
| "The 2015 AHA guidelines recommend that amiodarone should be used for patients with refractory ventricular fibrillation (RVF)." | 3.91 | Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data. ( Choi, HJ; Kim, G; Kim, YJ; Lee, CA; Lee, DK; Moon, HJ; Oh, J; Oh, YT; Park, SM; Yang, HC, 2019) |
| "This nationwide study suggested no significant in-hospital mortality association between nifekalant and amiodarone for cardiogenic out-of-hospital cardiac arrest patients with ventricular fibrillation/persistent ventricular tachycardia on hospital arrival." | 3.83 | Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest. ( Fukuda, R; Fushimi, K; Ishinokami, S; Kitahashi, A; Matsui, H; Oyanagi, M; Tagami, T; Unemoto, K; Yasunaga, H, 2016) |
| " Of these, 25 patients were treated with nifekalant or amiodarone in response to ventricular fibrillation that was resistant to two or more shocks." | 3.80 | Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation. ( Aibara, K; Goto, K; Harayama, N; Isa, Y; Kamochi, M; Nagata, K; Nihei, S; Sata, T, 2014) |
| "Amiodarone and lidocaine increase short-term outcomes, and point estimates suggest a small but uncertain effect on long-term survival." | 2.66 | Drugs during cardiopulmonary resuscitation. ( Andersen, LW; Granfeldt, A; Holmberg, MJ; Vallentin, MF, 2020) |
| "Amiodarone and lidocaine were the only agents associated with improved survival to hospital admission in the NMA." | 2.55 | Comparative effectiveness of antiarrhythmics for out-of-hospital cardiac arrest: A systematic review and network meta-analysis. ( Brignardello-Petersen, R; Cheskes, S; Guyatt, G; Iansavichene, A; McLeod, SL; Worster, A; You, J, 2017) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 29 (63.04) | 24.3611 |
| 2020's | 17 (36.96) | 2.80 |
| Authors | Studies |
|---|---|
| Lane, DJ | 1 |
| Grunau, B | 3 |
| Kudenchuk, P | 1 |
| Dorian, P | 8 |
| Wang, HE | 2 |
| Daya, MR | 3 |
| Lupton, J | 1 |
| Vaillancourt, C | 3 |
| Okubo, M | 1 |
| Davis, D | 1 |
| Rea, T | 3 |
| Yannopoulos, D | 2 |
| Christenson, J | 3 |
| Scheuermeyer, F | 1 |
| Rahimi, M | 2 |
| Cheskes, S | 4 |
| Lebovic, G | 2 |
| Lin, S | 2 |
| Huebinger, R | 2 |
| Chan, HK | 2 |
| Bobrow, B | 1 |
| Chavez, S | 1 |
| Schulz, K | 1 |
| Gordon, R | 1 |
| Jarvis, J | 1 |
| Harvin, JA | 1 |
| Idris, A | 2 |
| Cooper, B | 1 |
| Giordano, J | 1 |
| Wagner, D | 1 |
| Kronick, SL | 1 |
| Nawer, H | 1 |
| Cranford, JA | 1 |
| Bradley, SM | 1 |
| Neumar, RW | 2 |
| Kishihara, Y | 1 |
| Kashiura, M | 1 |
| Amagasa, S | 1 |
| Fukushima, F | 1 |
| Yasuda, H | 1 |
| Moriya, T | 1 |
| Zhou, D | 1 |
| Lv, Y | 1 |
| Lin, Q | 1 |
| Wang, C | 1 |
| Fei, S | 1 |
| He, W | 1 |
| Lupton, JR | 2 |
| Neth, MR | 1 |
| Sahni, R | 1 |
| Jui, J | 1 |
| Wittwer, L | 3 |
| Newgard, CD | 2 |
| Jouffroy, R | 1 |
| Ecollan, P | 1 |
| Chollet-Xemard, C | 1 |
| Prunet, B | 1 |
| Elie, C | 1 |
| Treluyer, JM | 1 |
| Vivien, B | 1 |
| Adler, C | 1 |
| Paul, C | 1 |
| Michels, G | 1 |
| Pfister, R | 1 |
| Sabashnikov, A | 1 |
| Hinkelbein, J | 1 |
| Braumann, S | 1 |
| Djordjevic, L | 1 |
| Blomeyer, R | 1 |
| Krings, A | 1 |
| Böttiger, BW | 2 |
| Baldus, S | 1 |
| Stangl, R | 1 |
| Lee, DK | 1 |
| Kim, YJ | 1 |
| Kim, G | 1 |
| Lee, CA | 1 |
| Moon, HJ | 1 |
| Oh, J | 1 |
| Yang, HC | 1 |
| Choi, HJ | 2 |
| Oh, YT | 1 |
| Park, SM | 1 |
| Bartos, JA | 1 |
| Carlson, C | 1 |
| Duval, S | 1 |
| Ripeckyj, A | 1 |
| Kalra, R | 1 |
| Raveendran, G | 1 |
| John, R | 1 |
| Conterato, M | 1 |
| Frascone, RJ | 1 |
| Trembley, A | 1 |
| Aufderheide, TP | 3 |
| Leroux, BG | 1 |
| Rea, TD | 1 |
| Morrison, LJ | 4 |
| Menegazzi, JJ | 2 |
| Ornato, JP | 2 |
| Sopko, G | 1 |
| Mody, P | 1 |
| Vilke, GM | 2 |
| Herdeman, C | 1 |
| Barbic, D | 1 |
| Kudenchuk, PJ | 5 |
| Vallentin, MF | 1 |
| Granfeldt, A | 1 |
| Holmberg, MJ | 1 |
| Andersen, LW | 2 |
| Ludwin, K | 1 |
| Smereka, J | 1 |
| Nadolny, K | 1 |
| Ładny, JR | 1 |
| Szarpak, A | 1 |
| Fajfer, Z | 1 |
| Jaguszewski, M | 1 |
| Filipiak, KJ | 1 |
| Szarpak, Ł | 1 |
| Baldi, E | 1 |
| Sechi, GM | 1 |
| Mare, C | 1 |
| Canevari, F | 1 |
| Brancaglione, A | 1 |
| Primi, R | 1 |
| Palo, A | 1 |
| Contri, E | 1 |
| Ronchi, V | 1 |
| Beretta, G | 1 |
| Reali, F | 1 |
| Parogni, PP | 1 |
| Facchin, F | 1 |
| Rizzi, U | 1 |
| Bussi, D | 1 |
| Ruggeri, S | 1 |
| Oltrona Visconti, L | 1 |
| Savastano, S | 1 |
| Noh, H | 1 |
| Wissa, J | 1 |
| Schultz, BV | 1 |
| Wilson, D | 1 |
| Rashford, S | 1 |
| Bosley, E | 1 |
| Doan, TN | 1 |
| Tagami, T | 3 |
| Yasunaga, H | 3 |
| Yokota, H | 1 |
| McLeod, SL | 1 |
| Brignardello-Petersen, R | 1 |
| Worster, A | 1 |
| You, J | 1 |
| Iansavichene, A | 1 |
| Guyatt, G | 1 |
| Soar, J | 3 |
| Salcido, DD | 1 |
| Schmicker, RH | 1 |
| Kime, N | 1 |
| Buick, JE | 1 |
| Zellner, S | 1 |
| Zive, D | 1 |
| Koller, AC | 1 |
| Herren, H | 1 |
| Nuttall, J | 1 |
| Sundermann, ML | 1 |
| Jarvis, JL | 1 |
| Lincoln, E | 1 |
| Ali, MU | 1 |
| Fitzpatrick-Lewis, D | 1 |
| Kenny, M | 1 |
| Raina, P | 1 |
| Atkins, DL | 3 |
| Nolan, J | 1 |
| Ristagno, G | 3 |
| Sherifali, D | 1 |
| Donnino, MW | 1 |
| Maconochie, I | 1 |
| Aickin, R | 1 |
| Berg, KM | 1 |
| Bingham, R | 1 |
| Callaway, CW | 2 |
| Couper, K | 1 |
| Couto, TB | 1 |
| de Caen, AR | 1 |
| Deakin, CD | 1 |
| Drennan, IR | 1 |
| Guerguerian, AM | 1 |
| Lavonas, EJ | 1 |
| Meaney, PA | 1 |
| Nadkarni, VM | 1 |
| Ng, KC | 1 |
| Nicholson, TC | 1 |
| Nuthall, GA | 1 |
| Ohshimo, S | 1 |
| O'Neil, BJ | 1 |
| Ong, GY | 1 |
| Paiva, EF | 1 |
| Parr, MJ | 1 |
| Reis, AG | 1 |
| Reynolds, JC | 1 |
| Sandroni, C | 1 |
| Schexnayder, SM | 1 |
| Scholefield, BR | 1 |
| Shimizu, N | 1 |
| Tijssen, JA | 1 |
| Van de Voorde, P | 1 |
| Wang, TL | 1 |
| Welsford, M | 1 |
| Hazinski, MF | 2 |
| Nolan, JP | 1 |
| Morley, PT | 1 |
| Duff, JP | 1 |
| Topjian, A | 1 |
| Berg, MD | 1 |
| Chan, M | 1 |
| Haskell, SE | 1 |
| Joyner, BL | 1 |
| Lasa, JJ | 1 |
| Ley, SJ | 1 |
| Raymond, TT | 1 |
| Sutton, RM | 1 |
| Harayama, N | 1 |
| Nihei, S | 1 |
| Nagata, K | 1 |
| Isa, Y | 1 |
| Goto, K | 1 |
| Aibara, K | 1 |
| Kamochi, M | 1 |
| Sata, T | 1 |
| Brown, SP | 3 |
| Daya, M | 4 |
| Grunau, BE | 1 |
| Aufderheide, T | 1 |
| Powell, J | 2 |
| Leroux, B | 3 |
| Larsen, J | 1 |
| Colella, MR | 2 |
| Stephens, SW | 1 |
| Gamber, M | 1 |
| Egan, D | 2 |
| Iannone, P | 1 |
| Fukuda, T | 1 |
| Nakamura, K | 1 |
| Fukuda-Ohashi, N | 1 |
| Yahagi, N | 1 |
| Amino, M | 1 |
| Inokuchi, S | 1 |
| Nagao, K | 1 |
| Nakagawa, Y | 1 |
| Yoshioka, K | 1 |
| Ikari, Y | 1 |
| Funakoshi, H | 1 |
| Hayakawa, K | 1 |
| Matsuzaki, M | 1 |
| Sakurai, A | 1 |
| Tahara, Y | 1 |
| Yonemoto, N | 1 |
| Yaguchi, A | 1 |
| Morimura, N | 1 |
| Sarrias, A | 1 |
| Villuendas, R | 1 |
| Bisbal, F | 1 |
| Pereferrer, D | 1 |
| Rueda, F | 1 |
| Serra, J | 1 |
| García, C | 1 |
| Bayés-Genís, A | 1 |
| Joglar, JA | 1 |
| Page, RL | 1 |
| Nichol, G | 1 |
| Weisfeldt, ML | 1 |
| Stiell, IG | 1 |
| Idris, AH | 1 |
| Dunford, JV | 1 |
| Brienza, AM | 1 |
| Desvigne-Nickens, P | 1 |
| Gray, PC | 1 |
| Gray, R | 1 |
| Seals, N | 1 |
| Straight, R | 1 |
| Mumma, BE | 1 |
| Umarov, T | 1 |
| Sanfilippo, F | 1 |
| Corredor, C | 1 |
| Santonocito, C | 1 |
| Panarello, G | 1 |
| Arcadipane, A | 1 |
| Pellis, T | 1 |
| Pollak, PT | 1 |
| Spence, JD | 1 |
| Patel, JJ | 1 |
| Matsui, H | 2 |
| Ishinokami, S | 2 |
| Oyanagi, M | 1 |
| Kitahashi, A | 1 |
| Fukuda, R | 1 |
| Unemoto, K | 2 |
| Fushimi, K | 2 |
| Tanaka, C | 1 |
| Kaneko, J | 1 |
| Kuno, M | 1 |
| Huang, CH | 1 |
| Yu, PH | 1 |
| Tsai, MS | 1 |
| Chuang, PY | 1 |
| Wang, TD | 1 |
| Chiang, CY | 1 |
| Chang, WT | 1 |
| Ma, MH | 1 |
| Tang, CH | 1 |
| Chen, WJ | 1 |
| Lang, ES | 1 |
| Browning, K | 1 |
| Santos, D | 1 |
| Carron, PN | 1 |
| Yersin, B | 1 |
| Pasquier, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| aMsa and amiOdarone Study in cArdiaC Arrest[NCT04997980] | 500 participants (Anticipated) | Observational | 2015-01-01 | Recruiting | |||
| Etiology, Incidence and Survival of Pediatric Out-of-hospital Cardiac Arrests: a Four-year Danish Analysis[NCT04275856] | 300 participants (Anticipated) | Observational [Patient Registry] | 2019-02-01 | Active, not recruiting | |||
| Amiodarone, Lidocaine or Neither for Out-Of-Hospital Cardiac Arrest Due to Ventricular Fibrillation (VF) or Ventricular Tachycardia (VT)[NCT01401647] | Phase 3 | 3,024 participants (Actual) | Interventional | 2012-05-31 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
Neurologic status at discharge will be assessed using the modified Rankin Score (MRS). A higher value indicates a worse outcome. 0-No symptoms at all; 1-No significant disability despite symptoms; able to carry out all usual duties and activities, 2-Slight disability; unable to carry out all previous activities, but able to look after own affairs without assistance, 3-Moderate disability; requiring some help, but able to walk without assistance; 4-Moderately severe disability; unable to walk without assistance and unable to attend to own bodily needs without assistance, 5-Severe disability; bedridden, incontinent and requiring constant nursing care and attention; 6-Dead (NCT01401647)
Timeframe: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
| Intervention | Participants (Count of Participants) |
|---|---|
| Amiodarone | 182 |
| Lidocaine | 172 |
| Normal Saline | 175 |
Patients may die in the field (outside of the hospital at the time of the cardiac arrest), at the emergency room, in the hospital, or they are discharged alive from the hospital. (NCT01401647)
Timeframe: Patients will be followed from the time of the cardiac arrest until death, hospital discharge, or December 31, 2015, whichever occurs first.
| Intervention | participants (Number) |
|---|---|
| Amiodarone | 237 |
| Lidocaine | 233 |
| Normal Saline | 222 |
10 reviews available for amiodarone and Out-of-Hospital Cardiac Arrest
| Article | Year |
|---|---|
Drugs during cardiopulmonary resuscitation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Epinephrine; Humans; Out-o | 2020 |
Effect of amiodarone and lidocaine on shock-refractory cardiac arrest: a systematic review and meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Cross-Sectional Studies; Humans; | 2020 |
Antiarrhythmic drugs for out-of-hospital cardiac arrest with refractory ventricular fibrillation.
Topics: Amiodarone; Anti-Arrhythmia Agents; Emergency Medical Services; Humans; Intensive Care Units; Lidoca | 2017 |
Comparative effectiveness of antiarrhythmics for out-of-hospital cardiac arrest: A systematic review and network meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Bretylium Compounds; Humans; Lidocaine; Network Meta-Analysis; O | 2017 |
Antiarrhythmic drug therapy during cardiopulmonary resuscitation: should we use it?
Topics: Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Arrhythmias, Cardiac; Cardiopulm | 2018 |
Antidysrhythmics in,Cardiac Arrest: What Does the Literature Say? Several have come and gone-what's the basis for using those still in our arsenal?
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Emerg | 2017 |
Effectiveness of antiarrhythmic drugs for shockable cardiac arrest: A systematic review.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Child; Female; Humans; Lid | 2018 |
Amiodarone or lidocaine for cardiac arrest: A systematic review and meta-analysis.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Hospitalization; Humans; Lidocain | 2016 |
Ventricular tachyarrhythmias (out-of-hospital cardiac arrests).
Topics: Amiodarone; Death, Sudden, Cardiac; Electric Countershock; Humans; Hypothermia, Induced; Lidocaine; | 2010 |
EZ-IO(®) intraosseous device implementation in a pre-hospital emergency service: A prospective study and review of the literature.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Analgesics; Anti-Arrhythmia Agents; Atropine | 2013 |
7 trials available for amiodarone and Out-of-Hospital Cardiac Arrest
| Article | Year |
|---|---|
Effect of Time to Treatment With Antiarrhythmic Drugs on Return of Spontaneous Circulation in Shock-Refractory Out-of-Hospital Cardiac Arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Humans; Lidocaine; Out-of- | 2022 |
Association between rate of change in PaCO
Topics: Amiodarone; Carbon Dioxide; Cardiopulmonary Resuscitation; Humans; Hypercapnia; Out-of-Hospital Card | 2023 |
Survival by time-to-administration of amiodarone, lidocaine, or placebo in shock-refractory out-of-hospital cardiac arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Hospi | 2023 |
Survival After Intravenous Versus Intraosseous Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Shock-Refractory Cardiac Arrest.
Topics: Administration, Intravenous; Aged; Amiodarone; Disease-Free Survival; Double-Blind Method; Female; H | 2020 |
Effects of intra-resuscitation antiarrhythmic administration on rearrest occurrence and intra-resuscitation ECG characteristics in the ROC ALPS trial.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Canada; Cardiopulmonary Resuscitation; Electrocardiography | 2018 |
Resuscitation Outcomes Consortium-Amiodarone, Lidocaine or Placebo Study (ROC-ALPS): Rationale and methodology behind an out-of-hospital cardiac arrest antiarrhythmic drug trial.
Topics: Adolescent; Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Dose-Response | 2014 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Adult; Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Central Nervous Syst | 2016 |
29 other studies available for amiodarone and Out-of-Hospital Cardiac Arrest
| Article | Year |
|---|---|
Bayesian analysis of amiodarone or lidocaine versus placebo for out-of-hospital cardiac arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Bayes Theorem; Humans; Lidocaine; Out-of-Hospital Cardiac | 2022 |
Time to Antiarrhythmic and Association with Return of Spontaneous Circulation in the United States.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services | 2023 |
Procainamide for shockable rhythm cardiac arrest in the Resuscitation Outcome Consortium.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Human | 2022 |
Comparative Effectiveness of Amiodarone and Lidocaine for the Treatment of In-Hospital Cardiac Arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Hospitals; Humans; Lidocai | 2023 |
Comparison of the effects of lidocaine and amiodarone for out-of-hospital cardiac arrest patients with shockable rhythms: a retrospective observational study from a multicenter registry.
Topics: Adult; Amiodarone; Cardiopulmonary Resuscitation; Electric Countershock; Emergency Medical Services; | 2022 |
Evaluation of the effectiveness of potassium chloride in the management of out-of hospital cardiac arrest by refractory ventricular fibrillation: Study protocol of the POTACREH study.
Topics: Amiodarone; Cardiopulmonary Resuscitation; Clinical Trials, Phase II as Topic; Electric Countershock | 2023 |
The Effect of Time to Treatment With Antiarrhythmic Drugs on Survival and Neurological Outcomes in Shock Refractory Out-of-Hospital Cardiac Arrest.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Humans; Lidocaine; Out-of- | 2023 |
One year experience with fast track algorithm in patients with refractory out-of-hospital cardiac arrest.
Topics: Adult; Aged; Algorithms; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Controll | 2019 |
Impact of early intravenous amiodarone administration on neurological outcome in refractory ventricular fibrillation: retrospective analysis of prospectively collected prehospital data.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; | 2019 |
Improved Survival With Extracorporeal Cardiopulmonary Resuscitation Despite Progressive Metabolic Derangement Associated With Prolonged Resuscitation.
Topics: Acidosis, Lactic; Advanced Cardiac Life Support; Amiodarone; Brain Damage, Chronic; Cardiopulmonary | 2020 |
Treatment of out-of-hospital cardiac arrest in the COVID-19 era: A 100 days experience from the Lombardy region.
Topics: Aged; Aged, 80 and over; Amiodarone; Betacoronavirus; Cardiopulmonary Resuscitation; Coronavirus Inf | 2020 |
Successful defibrillation using double sequence defibrillation: Case reports.
Topics: Adult; Amiodarone; Cardiopulmonary Resuscitation; Defibrillators; Electric Countershock; Electrocard | 2021 |
Time to amiodarone administration and survival outcomes in refractory ventricular fibrillation.
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services | 2021 |
2018 International Consensus on Cardiopulmonary Resuscitation and Emergency Cardiovascular Care Science With Treatment Recommendations Summary.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Consensus; Emergency Medical Serv | 2018 |
2018 American Heart Association Focused Update on Pediatric Advanced Life Support: An Update to the American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care.
Topics: American Heart Association; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Child | 2018 |
Comparison of nifekalant and amiodarone for resuscitation of out-of-hospital cardiopulmonary arrest resulting from shock-resistant ventricular fibrillation.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Dose-Response Relationship, | 2014 |
Letter to the editor regarding manuscript "resuscitation outcomes consortium-amiodarone, lidocaine or placebo: rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trial".
Topics: Amiodarone; Cardiopulmonary Resuscitation; Female; Humans; Lidocaine; Male; Out-of-Hospital Cardiac | 2014 |
Regarding manuscript: "resuscitation outcomes consortium-amiodarone, lidocaine, or placebo study: rationale and methodology behind out-of-hospital cardiac arrest antiarrhythmic drug trial".
Topics: Amiodarone; Cardiopulmonary Resuscitation; Female; Humans; Lidocaine; Male; Out-of-Hospital Cardiac | 2014 |
How long should resuscitative efforts be continued in adult out-of-hospital cardiac arrest?
Topics: Adult; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Electric Countershock; Eme | 2015 |
Nifekalant Hydrochloride and Amiodarone Hydrochloride Result in Similar Improvements for 24-Hour Survival in Cardiopulmonary Arrest Patients: The SOS-KANTO 2012 Study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Japan; Male; Middle Aged; Out-of-Hospital | 2015 |
From Atrial Fibrillation to Ventricular Fibrillation and Back.
Topics: Adult; Amiodarone; Atrial Fibrillation; Cardiopulmonary Resuscitation; Catheter Ablation; Combined M | 2015 |
Out-of-Hospital Cardiac Arrest--Are Drugs Ever the Answer?
Topics: Amiodarone; Anti-Arrhythmia Agents; Female; Humans; Lidocaine; Male; Out-of-Hospital Cardiac Arrest | 2016 |
Sex differences in the prehospital management of out-of-hospital cardiac arrest.
Topics: Aged; Aged, 80 and over; Amiodarone; Arrhythmias, Cardiac; Atropine; Cardiopulmonary Resuscitation; | 2016 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Heart | 2016 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Heart | 2016 |
Amiodarone, Lidocaine, or Placebo in Out-of-Hospital Cardiac Arrest.
Topics: Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Emergency Medical Services; Heart | 2016 |
Amiodarone or nifekalant upon hospital arrival for refractory ventricular fibrillation after out-of-hospital cardiac arrest.
Topics: Adolescent; Adult; Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Emergency Medical Se | 2016 |
Amiodarone Compared with Lidocaine for Out-Of-Hospital Cardiac Arrest with Refractory Ventricular Fibrillation on Hospital Arrival: a Nationwide Database Study.
Topics: Aged; Aged, 80 and over; Amiodarone; Anti-Arrhythmia Agents; Databases, Factual; Female; Hospital Mo | 2016 |
Acute hospital administration of amiodarone and/or lidocaine in shockable patients presenting with out-of-hospital cardiac arrest: A nationwide cohort study.
Topics: Aged; Amiodarone; Anti-Arrhythmia Agents; Cardiopulmonary Resuscitation; Electric Countershock; Fema | 2017 |